SCHEMBL5386137

SCHEMBL5386137

O=C(O)N1CCC(O)(c2cc(C(F)(F)F)ccc2Cl)CC1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 3/20 0.43
OPRL1 P41146 3/20 0.43
ALDH1A1 P00352 3/20 0.43
S1PR2 O95136 2/20 0.42
DRD2 P14416 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
MEN1 O00255 1/20 0.39
TSHR P16473 1/20 0.39
KMT2A Q03164 1/20 0.39
ATM Q13315 1/20 0.39
CHRM4 P08173 1/20 0.39
IDO1 P14902 1/20 0.39
TDO2 P48775 1/20 0.39
TRPM8 Q7Z2W7 1/20 0.39
FFAR4 Q5NUL3 1/20 0.38
POLB P06746 1/20 0.38
FAAH O00519 1/20 0.38
LMNA P02545 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5385954 0.85 S1PR2 (0.42) OPRM1OPRL1S1PR2TSHRCHRM4
SCHEMBL5371445 0.84 L3MBTL1 (0.44) OPRM1OPRL1S1PR2DRD2L3MBTL1
SCHEMBL5375085 0.82 DRD2 (0.51) ALDH1A1DRD2L3MBTL1MEN1TSHR
SCHEMBL23577913 0.77 OPRL1 (0.53) OPRM1OPRL1S1PR2DRD2MEN1
SCHEMBL2927759 0.77 OPRL1 (0.49) OPRM1OPRL1DRD2
SCHEMBL3387476 0.76 OPRM1 (0.61) OPRM1OPRL1DRD2
SCHEMBL2274921 0.76 DRD2 (0.42) OPRM1OPRL1ALDH1A1DRD2
SCHEMBL2925749 0.76 OPRM1 (0.63) OPRM1OPRL1MEN1TSHRKMT2A
SCHEMBL5368096 0.75 S1PR2 (0.49) OPRM1OPRL1S1PR2MEN1TSHR
SCHEMBL7959913 0.74 DRD2 (0.52) OPRM1OPRL1ALDH1A1DRD2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1714961-B1 INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2015-12-09 EP claimed
US-20070173537-A1 Indazole compound and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2007-07-26 US claimed
EP-1714961-A1 INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2006-10-25 EP claimed
EP-1714961-B1 INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2015-12-09 EP disclosed
US-20070173537-A1 Indazole compound and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2007-07-26 US disclosed
EP-1714961-A1 INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2006-10-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070173537-A1 Indazole compound and pharmaceutical use thereof CYP3A5, CYP3A43, TP53 OPRM1 3770/4885OPRL1 3885/4885ALDH1A1 92/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.